Key Melanoma Trials at ASCO Yield Encouraging Survival Data Key Melanoma Trials at ASCO Yield Encouraging Survival Data
The survival advantage seen in the COLUMBUS trial with a BRAF/MEK drug combination may be unprecedented, says Dr Jeffrey Weber.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

MAGE-A3 Immunotherapeutic Fails in Stage III Melanoma
An antigen-specific immunotherapeutic known as MAGE-A3 was no better than placebo for the adjuvant treatment of stage IIIB or IIIC melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 22, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Tremelimumab and Imfinzi Combo Effective for Mesothelioma
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination. The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine. Similar — or even more promising — results with this combination are expected to follow soon in the United States. “Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safe...
Source: Asbestos and Mesothelioma News - June 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

New therapeutic opportunity for the treatment of resistant malignant melanoma
(University of Liege) Researchers have revealed that malignant melanoma can reprogram their protein synthesis machinery and become addicted to a new family of enzymes that modify transfer RNAs during acquired resistance. The inhibition of these molecules synergies with targeted therapies to produce a strong anti-tumoral effect. These new findings will be key in the development of improved diagnostic tools and melanoma treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 20, 2018 Category: Cancer & Oncology Source Type: news

Ocular Melanoma (Intraocular Melanoma or Uveal Melanoma)
Title: Ocular Melanoma (Intraocular Melanoma or Uveal Melanoma)Category: Diseases and ConditionsCreated: 5/8/2018 12:00:00 AMLast Editorial Review: 6/19/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 19, 2018 Category: Cancer & Oncology Source Type: news

Mayo Clinic Q and A: Melanoma can begin in the eye
DEAR MAYO CLINIC: Is it true that melanoma can develop in the eyes? If so, how common is it? How is it treated? ANSWER:?Melanoma can begin in the eye ? a condition called intraocular melanoma. Treatment for intraocular melanoma used to primarily involve removing the affected eye. Now, however, radiation therapy often can be used [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 19, 2018 Category: Databases & Libraries Source Type: news

Genomics offers new treatment options for infants with range of soft tissue tumors
(Wellcome Trust Sanger Institute) The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed mutations which are targetable by existing drugs used to treat lung cancer and melanoma. The results have implications for clinical practice and the diagnosis of rare cancers in infants, and could lead to new, targeted treatment options for these children. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 18, 2018 Category: Biology Source Type: news

No difference in malignancy rates seen between tocilizumab and TNFi in patients with RA
(European League Against Rheumatism) The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) examined rates of malignancy in patients with rheumatoid arthritis (RA), excluding non-melanoma skin cancer (NMSC), and found no difference between those newly treated with tocilizumab (TCZ) versus TNF inhibitors (TNFi). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news

Cut your risk for liver cancer by HALF by just increasing your vitamin D levels
(Natural News) Did you know that roughly 38.4 percent of people will be diagnosed with some type of cancer during their lifetime? If you’re “lucky,” yours might just be a harmless melanoma that your dermatologist can remove in their office. If you’re really unlucky, on the other hand, you could end up with one of... (Source: NaturalNews.com)
Source: NaturalNews.com - June 15, 2018 Category: Consumer Health News Source Type: news

Nottingham beauty therapists taught to spot skin cancer signs
There are more than 2,400 deaths from melanoma every year, according to Cancer Research UK. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - June 14, 2018 Category: Consumer Health News Source Type: news

Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Phase 1/2 clinical trial in patients with advanced solid tumors that have progressed on anti-PD-1/PD-L1 therapy to evaluate APX005M in combination with cabiralizumab and Opdivo Study to enroll metastatic non-small cell lung cancer (NSCLC), metastatic me... Biopharmaceuticals, Oncology Apexigen, cabiralizumab, Opdivo, NSCLC, melanoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 14, 2018 Category: Pharmaceuticals Source Type: news

Older melanoma patients respond better to immunotherapy
Anti-PD1 immunotherapy more effectively treated older melanoma patients, according to researchers who see potential in better targeting it to younger patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 13, 2018 Category: Consumer Health News Source Type: news

Older melanoma patients may respond better to immunotherapy
Anti-PD1 immunotherapy more effectively treated older melanoma patients, according to researchers who see potential in better targeting it to younger patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 13, 2018 Category: Consumer Health News Source Type: news

Older melanoma patients have better response to immune checkpoint blockade therapy
(The Wistar Institute) Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 13, 2018 Category: International Medicine & Public Health Source Type: news

Older melanoma patients may respond to anti-PD1 immunotherapy better than younger patients
(American Association for Cancer Research) With each decade of life, the likelihood of progression of melanoma after treatment with anti-PD1 immunotherapy decreased by 13 percent. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 13, 2018 Category: International Medicine & Public Health Source Type: news

Uveal Melanoma: Better Survival With Liver-Directed Therapy Uveal Melanoma: Better Survival With Liver-Directed Therapy
Treatment for liver metastases in uveal cancer has changed over 50 years. At ASCO, one study charted the survival benefits seen with newer localized therapies; the other showed benefits of radioembolization.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Analysis Highlights Changes in 8th Edition AJCC Melanoma Staging System
“Now that effective adjuvant therapy has arrived in melanoma, accurate staging and patient selection to optimize a risk/benefit ratio is crucial,” emphasizes lead author Max Madu. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

T-VEC Immunotherapy Shows Promising Early Activity in Melanoma
Bryant FurlowJun 7, 2018The genetically engineered oncolytic herpes simplex virus produced promising clinical responses in stage IIIB –IVM1a melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Determining the Role of the Gut Microbiome in Melanoma Treated With Anti –PD-1 ICIs
Jennifer Wargo, MDJun 6, 2018Patients who responded to anti –PD-1 therapy and experienced prolonged progression-free survival had a much greater diversity of gut bacteria. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
Dave LevitanJun 6, 2018After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Different outdoor professions carry different risks for skin cancer
(Wiley) One of the main risk factors for non-melanoma skin cancer (NMSC), the most common cancer worldwide, is solar ultraviolet radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 6, 2018 Category: Cancer & Oncology Source Type: news

Middle-aged men and melanoma risk
By 65, Caucasian men are reportedly twice as likely as women to get melanoma. And not only are they more likely to develop melanoma, but also they often have a more aggressive form of the disease, according to a report from Blue Cross Blue Shield Association. "Melanoma is often believed to be 'just another skin [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 6, 2018 Category: Databases & Libraries Source Type: news

Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Dave LevitanJun 5, 2018Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Merck's Keytruda shows promise in treating advanced melanoma
(Reuters) - Merck& Co Inc said on Monday long-term data from its cancer immunotherapy Keytruda showed promise in treating advanced melanoma patients, a day after announcing positive lung cancer data from the same treatment. (Source: Reuters: Health)
Source: Reuters: Health - June 4, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
(Tonic Life Communications USA) Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy ® ). Current data show an overall response rate of 38 percent following treatment with the combination of tilsotolimod and ipilimumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2018 Category: International Medicine & Public Health Source Type: news

Drug a New Weapon Against Advanced Lung Tumors
The drug has also worked well against other cancers. When former President Jimmy Carter was diagnosed with melanoma that had spread to his brain several years ago, it was Keytruda that threw the cancer into remission by curtailing the action of a protein known as PD-L1. (Source: WebMD Health)
Source: WebMD Health - June 3, 2018 Category: Consumer Health News Source Type: news

Nektar And Bristol Hurtle Forward With Experimental Cancer Drug
Nektar Pharmaceuticals and Bristol-Myers Squibb said results for their experimental cancer drug, NKTR-214, pushing forward into late-stage trials testing the medicine against melanoma, renal cell carcinoma, and urothelial cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 2, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:NKTR NYSE:BMY Source Type: news

Skin cancer - how long can you spend in the sun this summer without getting melanoma?
SKIN cancer symptoms can develop by spending too much time in the sun, and your risk increases if you get sunburnt. How long can you spend in the sunshine during the hot weather, and how can you protect yourself from a melanoma? (Source: Daily Express - Health)
Source: Daily Express - Health - June 1, 2018 Category: Consumer Health News Source Type: news

Skin cancer warning - How long can you spend in the sun this summer?
SKIN cancer symptoms can develop by spending too much time in the sun, and your risk increases if you get sunburnt. How long can you spend in the sunshine during the hot weather, and how can you protect yourself from a melanoma? (Source: Daily Express - Health)
Source: Daily Express - Health - June 1, 2018 Category: Consumer Health News Source Type: news

Convolutional Neural Network Tops Clinicians for Melanoma ID
CNN receiver operating characteristic curve had higher specificity compared with dermatologists'(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 1, 2018 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pathology, Journal, Source Type: news

Convolutional Neural Network Tops Clinicians for Melanoma ID
FRIDAY, June 1, 2018 -- The diagnostic performance of a deep learning convolutional neural network (CNN) seems better than that of dermatologists, according to a study published online May 28 in the Annals of Oncology. Holger A. Haenssle, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 1, 2018 Category: Pharmaceuticals Source Type: news

Cleveland Clinic Cancer Center experts present data at 2018 ASCO Annual Meeting
(Cleveland Clinic) At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, researchers from Cleveland Clinic Cancer Center will present data from several new studies, including a prospective clinical trial examining non-small cell lung cancer cells' response to immunotherapy; research on germline testing for melanoma; and interim results from a study testing a vaccine for glioblastoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2018 Category: International Medicine & Public Health Source Type: news

Sidney Kimmel Cancer Center scientists to present at ASCO Annual Meeting
(Thomas Jefferson University) Scientists from the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health will be presenting research and leading discussions on various topics, including metastatic uveal melanoma, genetic counseling in men, immunotherapy in early stage lung cancer and solid tumors, quality of life among patients receiving treatment for T cell lymphoma and updates on the Cancer Moonshot during the Biden Cancer Initiative Colloquium at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 1-5 in Chicago. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2018 Category: Cancer & Oncology Source Type: news

New procedure allows quick recovery for melanoma patients
A doctor at the University of Alabama at Birmingham has developed a new procedure that helps melanoma patients recover in a shorter amount of time. Carlo Contreras, assistant professor in the Division of Surgical Oncology and associate scientist with the UAB Comprehensive Cancer Center, discovered a minimally invasive approach to removing lymph nodes that UAB says isn’t offered anywhere else in the state. The procedure involves six small l aparoscopic incisions, whereas the traditional operation… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 31, 2018 Category: Health Management Authors: Angel Coker Source Type: news

Despite risk of breast cancer, few men undergo genetic tests, study finds
Cancer is one of the leading causes of death among Americans. At least 10 percent of cancers are caused by inherited mutations in genes such as BRCA1 and BRCA2. Parents with the cancer gene mutation have a 50 percent chance of passing it on to a son or daughter. It ’s well-known that women with BRCA are at a very high risk for breast and ovarian cancer. Less known is the fact that men with these mutations also are at risk of breast cancer and other cancers.Astudy published in April in JAMA Oncology finds that few men are screened for these genetic mutations — and the researchers strongly suggest that they be sc...
Source: UCLA Newsroom: Health Sciences - May 31, 2018 Category: Universities & Medical Training Source Type: news

FDA OKs First Artificial Iris for Aniridia, Other Iris Defects FDA OKs First Artificial Iris for Aniridia, Other Iris Defects
The CustomFlex Artificial Iris treats adults and children with congenital aniridia or iris defects due to other reasons or conditions, such as albinism, traumatic injury, or surgical removal due to melanoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2018 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news

FDA clears first artificial iris from HumanOptics
The FDA today granted pre-market approval and a breakthrough device designation for HumanOptics‘ CustomFlex artificial iris, touting it as the first stand-alone prosthetic iris to win approval in the US. The CustomFlex artificial iris is designed to be surgically implanted in adults and children to treat individuals whose iris is completely missing or damaged due to either a congenital condition called aniridia or other damage to the eye, according to an FDA release. The newly cleared device is also indicated to treat iris defects due to other reasons or conditions, such as albinism, traumatic injury or surgical remo...
Source: Mass Device - May 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Optical/Ophthalmic Pre-Market Approval (PMA) Regulatory/Compliance humanoptics Source Type: news

FDA Approves First Artificial Iris
A German company has become the first to score FDA approval for a stand-alone prosthetic iris in the United States. The agency said Wednesday afternoon that it approved the CustomFlex Artificial Iris, made by Erlangen, Germany-based HumanOptics. The device, which is surgically implanted, is approved to treat adults and children whose iris is completely missing or damaged due to a congenital condition called aniridia or other damage to the eye. “Patients with iris defects may experience severe vision problems, as well as dissatisfaction with the appearance of their eye,” said Malvina Eydelman, MD, dire...
Source: MDDI - May 30, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Implants Source Type: news

Possible Link Between Hydrochlorothiazide and Malignant Melanoma Possible Link Between Hydrochlorothiazide and Malignant Melanoma
Long-term hydrochlorothiazide use appears to be associated with an increased risk of malignant melanoma, researchers from Denmark report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO Preview: Melanoma Study Highlights
Ryan J. Sullivan, MDMay 30, 2018Medical oncologist Ryan J. Sullivan shared some interesting melanoma-related presentations that he wants to attend at ASCO 2018. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2018 Category: Cancer & Oncology Authors: A Source Type: news

ASCO 2018 Highlights: Melanoma Studies
Ryan J. Sullivan, MDMay 30, 2018Medical oncologist Ryan J. Sullivan shared some interesting melanoma-related presentations from the   2018 ASCO meeting. (Source: CancerNetwork)
Source: CancerNetwork - May 30, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Hydrochlorothiazide Tied to Increased Melanoma Risk
(MedPage Today) -- Possible link pronounced for lentigo and nodular subtypes (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 29, 2018 Category: Dermatology Source Type: news

Bots on Dots: Machines Screen for Melanoma
(MedPage Today) -- And the algorithms may just out-diagnose trained dermatologists (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - May 29, 2018 Category: Hematology Source Type: news

Medical News Today: Weight loss reduces skin cancer risk
A recent study followed individuals who had undergone obesity surgery. They found that the procedure significantly reduced their risk of skin cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 26, 2018 Category: Consumer Health News Tags: Melanoma / Skin Cancer Source Type: news

Science Saturday: Arresting melanoma's molecular drivers
Melanoma, the skin cancer often associated with sun exposure, is on the rise and has no reliable cure. May is National Melanoma and Skin Cancer Awareness Month, aimed at increasing early detection and treatment of this aggressive disease. Mayo Clinic is at the forefront of these efforts. The Center for Individualized Medicine (CIM) is unravelling [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 26, 2018 Category: Databases & Libraries Source Type: news

MEK/BRAF Inhibition May Overcome Molecular Heterogeneity of BRAF-Mutant Melanoma
Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600 –mutated melanoma. (Source: CancerNetwork)
Source: CancerNetwork - May 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Melanoma SiteTerms/www.cannabissciencetech.com/News Source Type: news

Big Drop in Malignant Melanoma Rate After Bariatric Surgery Big Drop in Malignant Melanoma Rate After Bariatric Surgery
Weight loss surgery for obesity appears to result in a huge reduction in the risk of malignant melanoma that persists for up to 20 years, according to a new analysis of long-term data from the SOS study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 24, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Another Foe for the U.S. Military: Skin Cancer
THURSDAY, May 24, 2018 -- For U.S. military personnel, deployment carries many dangers. And besides the well-known threats they face, these men and women are also at a higher-than-average risk for skin cancer, including potentially deadly melanoma,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 24, 2018 Category: General Medicine Source Type: news

Weight-loss surgery is associated with a reduced risk of melanoma, researchers say
In addition to rapid and lasting weight loss and a passel of other health benefits, bariatric surgery has now been linked to a 61% reduction in the risk of developing malignant melanoma, a deadly form of skin cancer most closely associated with excessive sun exposure.Thenew research, to be presented... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - May 24, 2018 Category: Science Authors: Melissa Healy Source Type: news